Demographics of combined cohort stratified by initial disease state
| . | NIH-BOS (n = 47) . | Early BOS (n = 13) . | Mixed BOS (n = 6) . | Transient impairment (n = 8) . | Control (n = 10) . | P value∗ . |
|---|---|---|---|---|---|---|
| Age, y (mean, SD) | 53.6 (14.1) | 54.9 (14.5) | 55.8 (13.8) | 43.8 (15.6) | 46.3 (15.9) | .24 |
| Sex (male, n, %) | 19 (40.4) | 7 (53.8) | 3 (50.0) | 5 (62.5) | 6 (60.0) | .64 |
| Race/ethnicity (n, %) | .91 | |||||
| Asian | 6 (12.8) | 1 (7.7) | 1 (16.7) | 3 (37.5) | 1 (10.0) | |
| Black | 1 (2.1) | 0 | 0 | 0 | 0 | |
| Latino | 6 (12.8) | 2 (15.4) | 0 | 1 (12.5) | 1 (10.0) | |
| White | 34 (72.3) | 10 (76.9) | 5 (83.3) | 4 (50.0) | 8 (80.0) | |
| Indication for transplant (n, %) | .01 | |||||
| ALL | 8 (17.0) | 0 | 1 (16.7) | 3 (37.5) | 1 (10.0) | |
| AML | 19 (40.4) | 5 (38.5) | 3 (50.0) | 2 (25.0) | 2 (20.0) | |
| Aplastic anemia | 0 | 0 | 0 | 0 | 2 (20.0) | |
| CLL | 2 (4.3) | 0 | 0 | 0 | 3 (30.0) | |
| CML | 2 (4.3) | 2 (15.4) | 0 | 1 (12.5) | 0 | |
| CMML | 1 (2.1) | 0 | 0 | 0 | 0 | |
| GATA immunodeficiency | 0 | 0 | 1 (16.7) | 0 | 0 | |
| HD | 0 | 1 (7.7) | 1 (16.7) | 0 | 1 (10.0) | |
| MDS | 8 (17.0) | 3 (23.1) | 0 | 1 (12.5) | 0 | |
| Myelofibrosis | 3 (6.4) | 1 (7.7) | 0 | 0 | 0 | |
| NHL | 4 (8.5) | 1 (7.7) | 0 | 1 (12.5) | 1 (10.0) | |
| Donor CMV positive (n, %) | 25 (53.2) | 7 (53.8) | 3 (50.0) | 7 (87.5) | 4 (40.0) | .35 |
| Recipient CMV positive (n, %) | 29 (61.7) | 8 (61.5) | 3 (50.0) | 6 (75.0) | 3 (30.0) | .32 |
| Matching status (n, %) | .001 | |||||
| Haploidentical | 2 (4.3) | 0 | 0 | 0 | 1 (10.0) | |
| Matched related donor | 24 (51.1) | 6 (46.2) | 3 (50.0) | 3 (37.5) | 4 (40.0) | |
| Matched unrelated donor | 21 (44.7) | 7 (53.8) | 2 (33.3) | 5 (62.5) | 0 | |
| Umbilical cord blood | 0 | 0 | 0 | 0 | 1 (10.0) | |
| Unrelated donor | 0 | 0 | 1 (16.7) | 0 | 4 (40.0) | |
| Myeloablative conditioning (n, %) | 33 (70.2) | 8 (61.5) | 3 (50.0) | 7 (87.5) | 5 (50.0) | .41 |
| Acute GVHD (n, %) | 34 (72.3) | 9 (69.2) | 1 (16.7) | 4 (50.0) | 4 (40.0) | .04 |
| Nonpulmonary organs with cGVHD (mean, SD) | 2.64 (1.45) | 2.64 (1.03) | 3.00 (1.10) | 1.67 (1.15) | 1.50 (0.76) | .12 |
| Pre-HCT FEV1 L/s (mean, SD) | 2.92 (0.63) | 3.23 (1.00) | 2.82 (0.78) | 3.32 (0.62) | 3.00 (0.63) | .49 |
| Pre-HCT FEV1 percent predicted (mean, SD) | 98.48 (20.24) | 96.77 (12.47) | 95.50 (20.11) | 102.88 (10.51) | 90.80 (9.40) | .65 |
| Pre-HCT FVC L/s (mean, SD) | 3.79 (0.86) | 4.13 (1.12) | 3.76 (0.93) | 4.05 (0.75) | 3.79 (0.85) | .82 |
| Pre-HCT FVC percent predicted (mean, SD) | 98.97 (18.46) | 96.31 (10.44) | 94.50 (18.04) | 103.38 (11.55) | 88.70 (6.86) | .31 |
| Months from HCT to study onset (mean, SD) | 35.89 (41.79) | 24.12 (16.14) | 54.82 (21.30) | 34.50 (37.02) | 41.67 (35.15) | .53 |
| . | NIH-BOS (n = 47) . | Early BOS (n = 13) . | Mixed BOS (n = 6) . | Transient impairment (n = 8) . | Control (n = 10) . | P value∗ . |
|---|---|---|---|---|---|---|
| Age, y (mean, SD) | 53.6 (14.1) | 54.9 (14.5) | 55.8 (13.8) | 43.8 (15.6) | 46.3 (15.9) | .24 |
| Sex (male, n, %) | 19 (40.4) | 7 (53.8) | 3 (50.0) | 5 (62.5) | 6 (60.0) | .64 |
| Race/ethnicity (n, %) | .91 | |||||
| Asian | 6 (12.8) | 1 (7.7) | 1 (16.7) | 3 (37.5) | 1 (10.0) | |
| Black | 1 (2.1) | 0 | 0 | 0 | 0 | |
| Latino | 6 (12.8) | 2 (15.4) | 0 | 1 (12.5) | 1 (10.0) | |
| White | 34 (72.3) | 10 (76.9) | 5 (83.3) | 4 (50.0) | 8 (80.0) | |
| Indication for transplant (n, %) | .01 | |||||
| ALL | 8 (17.0) | 0 | 1 (16.7) | 3 (37.5) | 1 (10.0) | |
| AML | 19 (40.4) | 5 (38.5) | 3 (50.0) | 2 (25.0) | 2 (20.0) | |
| Aplastic anemia | 0 | 0 | 0 | 0 | 2 (20.0) | |
| CLL | 2 (4.3) | 0 | 0 | 0 | 3 (30.0) | |
| CML | 2 (4.3) | 2 (15.4) | 0 | 1 (12.5) | 0 | |
| CMML | 1 (2.1) | 0 | 0 | 0 | 0 | |
| GATA immunodeficiency | 0 | 0 | 1 (16.7) | 0 | 0 | |
| HD | 0 | 1 (7.7) | 1 (16.7) | 0 | 1 (10.0) | |
| MDS | 8 (17.0) | 3 (23.1) | 0 | 1 (12.5) | 0 | |
| Myelofibrosis | 3 (6.4) | 1 (7.7) | 0 | 0 | 0 | |
| NHL | 4 (8.5) | 1 (7.7) | 0 | 1 (12.5) | 1 (10.0) | |
| Donor CMV positive (n, %) | 25 (53.2) | 7 (53.8) | 3 (50.0) | 7 (87.5) | 4 (40.0) | .35 |
| Recipient CMV positive (n, %) | 29 (61.7) | 8 (61.5) | 3 (50.0) | 6 (75.0) | 3 (30.0) | .32 |
| Matching status (n, %) | .001 | |||||
| Haploidentical | 2 (4.3) | 0 | 0 | 0 | 1 (10.0) | |
| Matched related donor | 24 (51.1) | 6 (46.2) | 3 (50.0) | 3 (37.5) | 4 (40.0) | |
| Matched unrelated donor | 21 (44.7) | 7 (53.8) | 2 (33.3) | 5 (62.5) | 0 | |
| Umbilical cord blood | 0 | 0 | 0 | 0 | 1 (10.0) | |
| Unrelated donor | 0 | 0 | 1 (16.7) | 0 | 4 (40.0) | |
| Myeloablative conditioning (n, %) | 33 (70.2) | 8 (61.5) | 3 (50.0) | 7 (87.5) | 5 (50.0) | .41 |
| Acute GVHD (n, %) | 34 (72.3) | 9 (69.2) | 1 (16.7) | 4 (50.0) | 4 (40.0) | .04 |
| Nonpulmonary organs with cGVHD (mean, SD) | 2.64 (1.45) | 2.64 (1.03) | 3.00 (1.10) | 1.67 (1.15) | 1.50 (0.76) | .12 |
| Pre-HCT FEV1 L/s (mean, SD) | 2.92 (0.63) | 3.23 (1.00) | 2.82 (0.78) | 3.32 (0.62) | 3.00 (0.63) | .49 |
| Pre-HCT FEV1 percent predicted (mean, SD) | 98.48 (20.24) | 96.77 (12.47) | 95.50 (20.11) | 102.88 (10.51) | 90.80 (9.40) | .65 |
| Pre-HCT FVC L/s (mean, SD) | 3.79 (0.86) | 4.13 (1.12) | 3.76 (0.93) | 4.05 (0.75) | 3.79 (0.85) | .82 |
| Pre-HCT FVC percent predicted (mean, SD) | 98.97 (18.46) | 96.31 (10.44) | 94.50 (18.04) | 103.38 (11.55) | 88.70 (6.86) | .31 |
| Months from HCT to study onset (mean, SD) | 35.89 (41.79) | 24.12 (16.14) | 54.82 (21.30) | 34.50 (37.02) | 41.67 (35.15) | .53 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CMML, chronic myelomonocytic leukemia; CML, chronic myelogenous leukemia; CMV, cytomegalovirus; FVC, forced vital capacity; HD, Hodgkin disease; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma.
Kruskal-Wallis test was used for group-wise statistical significance.